• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

美国的儿科介入心脏病学依赖于医疗器械的非标签使用。

Pediatric interventional cardiology in the United States is dependent on the off-label use of medical devices.

作者信息

Sutherell Jamie S, Hirsch Russel, Beekman Robert H

机构信息

Division of Cardiology, The Heart Institute at Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

出版信息

Congenit Heart Dis. 2010 Jan-Feb;5(1):2-7. doi: 10.1111/j.1747-0803.2009.00364.x.

DOI:10.1111/j.1747-0803.2009.00364.x
PMID:20136851
Abstract

OBJECTIVE

A substantial unmet medical device need exists in pediatric care. As a result, the off-label use of approved devices is routine in pediatric interventional cardiology, but the extent and nature of this practice has not been previously described. The purpose of this study, therefore, is to evaluate the prevalence and nature of off-label cardiac device use in an active pediatric interventional program in the United States.

STUDY DESIGN

This study is a retrospective review of all interventional cardiac procedures performed at our institution from July 1, 2005 to June 30, 2008. Diagnostic (noninterventional) catheterizations, myocardial biopsies, invasive electrophysiology studies, and studies involving investigational devices were excluded. Interventions performed were compared with the manufacturer's labeled indications for each device.

RESULTS

During this 3-year period, 473 patients (median age 4.1 years) underwent 595 transcatheter interventions. An approved device was utilized for an off-label application in 63% of patients, and in 50% of all interventions performed. The most frequent off-label procedures were stent implantations (99% off-label), balloon dilations (78% off-label), and coil embolizations (29% off-label). In contrast, the off-label use of septal and ductal occluders was relatively uncommon.

CONCLUSIONS

In our routine (noninvestigational) practice of pediatric interventional cardiology, 63% of patients underwent procedures utilizing medical devices for off-label indications. These data underscore the need to enhance cardiac device review and approval processes in the United States to include pediatric applications.

摘要

目的

儿科护理中存在大量未满足的医疗设备需求。因此,在儿科介入心脏病学中,批准设备的标签外使用很常见,但这种做法的程度和性质此前尚未有描述。因此,本研究的目的是评估美国一个活跃的儿科介入项目中心脏设备标签外使用的发生率和性质。

研究设计

本研究是对2005年7月1日至2008年6月30日在我们机构进行的所有心脏介入手术的回顾性研究。排除诊断性(非介入性)心导管检查、心肌活检、有创电生理研究以及涉及研究性设备的研究。将所进行的干预措施与每个设备制造商标注的适应症进行比较。

结果

在这3年期间,473例患者(中位年龄4.1岁)接受了595次经导管介入治疗。63%的患者使用批准的设备进行了标签外应用,占所有进行的干预措施的50%。最常见的标签外手术是支架植入(99%为标签外)、球囊扩张(78%为标签外)和弹簧圈栓塞(29%为标签外)。相比之下,房间隔和动脉导管封堵器的标签外使用相对少见。

结论

在我们儿科介入心脏病学的常规(非研究性)实践中,63%的患者接受了使用医疗设备进行标签外适应症的手术。这些数据强调了在美国加强心脏设备审查和批准程序以纳入儿科应用的必要性。

相似文献

1
Pediatric interventional cardiology in the United States is dependent on the off-label use of medical devices.美国的儿科介入心脏病学依赖于医疗器械的非标签使用。
Congenit Heart Dis. 2010 Jan-Feb;5(1):2-7. doi: 10.1111/j.1747-0803.2009.00364.x.
2
Advances in paediatric interventional cardiology since 2000.2000年以来小儿介入心脏病学的进展
Arch Cardiovasc Dis. 2009 Jun-Jul;102(6-7):569-82. doi: 10.1016/j.acvd.2009.04.006. Epub 2009 Jul 28.
3
The off-versus on-label use of medical devices in interventional cardiovascular medicine?: Clarifying the ambiguity between regulatory labeling and clinical decision making, part III: structural heart disease interventions.
Catheter Cardiovasc Interv. 2008 Nov 15;72(6):848-52. doi: 10.1002/ccd.21708.
4
Off-label does not mean off-base.未按药品说明书用药并不意味着不合理。
J Vasc Interv Radiol. 2008 Jul;19(7):970-1. doi: 10.1016/j.jvir.2008.04.022. Epub 2008 Jun 2.
5
Pathways to approval of pediatric cardiac devices in the United States: challenges and solutions.美国儿科心脏设备的批准途径:挑战与解决方案
Pediatrics. 2009 Jul;124(1):e155-62. doi: 10.1542/peds.2008-3726.
6
Shunt reduction with a fenestrated Amplatzer device.使用带孔的 Amplatzer 装置减少分流。
Catheter Cardiovasc Interv. 2010 Oct 1;76(4):564-71. doi: 10.1002/ccd.22556.
7
The "art" of medicine and the "smokescreen" of the randomized trial off-label use of vascular devices.医学“艺术”与血管装置标签外使用随机试验的“烟幕”
Catheter Cardiovasc Interv. 2008 Dec 1;72(7):998-1002. doi: 10.1002/ccd.21776.
8
Transcatheter closure of secundum atrial septal defect using the Amplatzer Septal Occluder: initial results of a single medical center in Taiwan.使用Amplatzer房间隔封堵器经导管闭合继发孔型房间隔缺损:台湾某单一医学中心的初步结果
Acta Paediatr Taiwan. 2005 Jan-Feb;46(1):17-23.
9
Overview of the 2006 Food and Drug Administration Circulatory System Devices Panel meeting on drug-eluting stent thrombosis.2006年美国食品药品监督管理局循环系统器械小组关于药物洗脱支架血栓形成会议综述
Catheter Cardiovasc Interv. 2007 Jun 1;69(7):1064-74. doi: 10.1002/ccd.21179.
10
First experience with the BioSTAR-device for various applications in pediatric patients with congenital heart disease.首例应用 BioSTAR 装置于先天性心脏病儿科患者的各种适应证。
Catheter Cardiovasc Interv. 2010 Jan 1;75(1):72-7. doi: 10.1002/ccd.22233.

引用本文的文献

1
Largest Single-Center Experience Using the Micro Vascular Plug (MVP) for Transcatheter Closure of Premature Patent Ductus Arteriosus.使用微血管封堵器(MVP)经导管闭合早产儿动脉导管未闭的最大单中心经验。
Pediatr Cardiol. 2025 Mar 27. doi: 10.1007/s00246-025-03832-6.
2
FDA Approval of Cardiac Valve Devices Implanted in a National Cohort of Pediatric Patients, 2016-2022.2016 - 2022年美国儿科患者全国队列中心脏瓣膜装置的FDA批准情况
JAMA Pediatr. 2025 May 1;179(5):570-573. doi: 10.1001/jamapediatrics.2025.0131.
3
Pediatric Electrophysiology Device Needs: A Survey from the Pediatric and Congenital Electrophysiology Society Taskforce on Pediatric-Specific Devices.
儿科电生理学设备需求:儿科和先天性电生理学学会专门设备工作组的调查。
J Am Heart Assoc. 2022 Nov 15;11(22):e026904. doi: 10.1161/JAHA.122.026904. Epub 2022 Nov 3.
4
Orphan Medical Devices and Pediatric Cardiology - What Interventionists in Europe Need to Know, and What Needs to be Done.罕见医疗器械与儿科心脏病学——欧洲介入医生应知应晓及需付诸行动的事项
Pediatr Cardiol. 2023 Feb;44(2):271-279. doi: 10.1007/s00246-022-03029-1. Epub 2022 Oct 18.
5
The European Medical Device Regulation-What Biomedical Engineers Need to Know.《欧盟医疗器械法规——生物医学工程师须知》。
IEEE J Transl Eng Health Med. 2022 Jul 28;10:4800105. doi: 10.1109/JTEHM.2022.3194415. eCollection 2022.
6
US Food and Drug Administration Approval of High-risk Cardiovascular Devices for Use in Children and Adolescents, 1977-2021.美国食品和药物管理局批准高风险心血管设备用于儿童和青少年,1977-2021 年。
JAMA. 2022 Aug 9;328(6):580-582. doi: 10.1001/jama.2022.10041.
7
An Up-to-Date Narrative Review on Congenital Heart Disease Percutaneous Treatment in Children Using Contemporary Devices.关于使用当代设备对儿童先天性心脏病进行经皮治疗的最新叙述性综述。
Diagnostics (Basel). 2022 May 10;12(5):1189. doi: 10.3390/diagnostics12051189.
8
Quantification of US Food and Drug Administration Premarket Approval Statements for High-Risk Medical Devices With Pediatric Age Indications.高风险医疗器械有儿科适应证的美国食品和药物管理局上市前批准声明的定量评估。
JAMA Netw Open. 2021 Jun 1;4(6):e2112562. doi: 10.1001/jamanetworkopen.2021.12562.
9
Experience With Pediatric Medical Device Development.儿科医疗器械开发经验
Front Pediatr. 2020 Apr 7;8:79. doi: 10.3389/fped.2020.00079. eCollection 2020.
10
A model for overcoming challenges in academic pediatric medical device innovation.一种克服学术性儿科医疗设备创新挑战的模式。
J Clin Transl Sci. 2019 Feb;3(1):5-11. doi: 10.1017/cts.2019.370.